<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Buprenorphine</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00921</strong>&#160; (APRD00670)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, illicit, investigational</td></tr><tr><th>Description</th><td><p>Buprenorphine is a derivative of the opioid alkaloid thebaine that is a more potent (25 &#8211; 40 times) and longer lasting analgesic than morphine. It appears to act as a partial agonist at mu and kappa opioid receptors and as an antagonist at delta receptors. The lack of delta-agonist activity has been suggested to account for the observation that buprenorphine tolerance may not develop with chronic use. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00921/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00921/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00921.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00921.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00921.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00921.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00921.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00921">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>(&#8722;)-buprenorphine</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Buprenophine</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Buprenorfina</td><td>Spanish</td><td>INN</td></tr><tr><td>Buprenorphinum</td><td>Latin</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Buprenorphine Hydrochloride </strong>
          <div class="cas">53152-21-9</div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000019/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000019/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: UAIXRPCCYXNJMQ-RZIPZOSSSA-N</li>
              <li>Monoisotopic Mass: 503.280236544</li>
              <li>Average Mass: 504.101</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000019">DBSALT000019</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Addnok</td><td>Rusan Pharma Ltd.</td></tr><tr><td>Buprel</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Buprenex</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Buprigesic</td><td>Neon Laboratories</td></tr><tr><td>Butrans</td><td>Purdue Pharma L.P.</td></tr><tr><td>Morgesic</td><td>Samarth Pharma</td></tr><tr><td>Norphin</td><td>Unichem Laboratories</td></tr><tr><td>Norspan</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Probuphine</td><td>Titan Pharmaceuticals, Inc.</td></tr><tr><td>Subutex</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Temgesic</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Tidigesic</td><td>Sun Pharmaceuticals</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>Suboxone </td><td>Buprenorphine + Naloxone </td></tr><tr><td>Zubsolv</td><td>Buprenorphine + Naloxone </td></tr></tbody></table></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/analgesics-opioid">Analgesics, Opioid</a></li>
<li><a href="/mesh/narcotics">Narcotics</a></li>
<li><a href="/mesh/narcotic-antagonists">Narcotic Antagonists</a></li></ul></td></tr><tr><th>CAS number</th><td>52485-79-7</td></tr><tr><th>Weight</th><td>Average: 467.6401<br>Monoisotopic: 467.303558805</td></tr><tr><th>Chemical Formula</th><td>C<sub>29</sub>H<sub>41</sub>NO<sub>4</sub></td></tr><tr><th>InChI Key</th><td>RMRJXGBAOAMLHD-IHFGGWKQSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C29H41NO4/c1-25(2,3)26(4,32)20-15-27-10-11-29(20,33-5)24-28(27)12-13-30(16-17-6-7-17)21(27)14-18-8-9-19(31)23(34-24)22(18)28/h8-9,17,20-21,24,31-32H,6-7,10-16H2,1-5H3/t20-,21-,24-,26+,27-,28+,29-/m1/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">(1S,2R,6S,14R,15R,16R)-3-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylbutan-2-yl]-15-methoxy-13-oxa-3-azahexacyclo[13.2.2.1^{2,8}.0^{1,6}.0^{6,14}.0^{7,12}]icosa-7,9,11-trien-11-ol</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1CC4=C5C(O[C@@H]2[C@@]35CCN1CC1CC1)=C(O)C=C4</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Alkaloids and Derivatives</td></tr><tr><th>Class</th><td>Morphinans</td></tr><tr><th>Subclass</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Direct parent</th><td>Morphinans</td></tr><tr><th>Alternative parents</th><td>Benzylisoquinolines; Phenanthrenes and Derivatives; Tetralins; Azaspirodecane Derivatives; Benzofurans; Phenols and Derivatives; Alkyl Aryl Ethers; Piperidines; Tertiary Alcohols; Tertiary Amines; Enols; Polyamines</td></tr><tr><th>Substituents</th><td>phenanthrene; tetralin; azaspirodecane; benzofuran; alkyl aryl ether; phenol derivative; benzene; piperidine; tertiary alcohol; tertiary amine; polyamine; ether; enol; amine; alcohol; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the morphinans. These are polycyclic compounds with a four-ring skeleton with three condensed six-member rings forming a partially hydrogenated phenanthrene moiety, one of which is aromatic while the two others are alicyclic.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of moderate to severe pain, peri-operative analgesia, and opioid dependence.</td></tr><tr><th>Pharmacodynamics</th><td>Buprenorphine is a synthetic opioid analgesic and thebaine derivative, with a longer duration of action than morphine. Buprenorphine interacts predominately with the opioid mu-receptor. These mu-binding sites are discretely distributed in the human brain, spinal cord, and other tissues. In clinical settings, buprenorphine exerts its principal pharmacologic effects on the central nervous system. Its primary actions of therapeutic value are analgesia and sedation. Buprenorphine may increase the patient's tolerance for pain and decrease the perception of suffering, although the presence of the pain itself may still be recognized. In addition to analgesia, alterations in mood, euphoria and dysphoria, and drowsiness commonly occur. Buprenorphine depresses the respiratory centers, depresses the cough reflex, and constricts the pupils. Pharmacological effects peaks at 15 minutes and persists for 6 hours or longer when given intramuscularly. When given intravenously, the time to onset and peak effect are shortened. </td></tr><tr><th>Mechanism of action</th><td>Buprenorphine's analgesic effect is due to partial agonist activity at mu-opioid receptors. Buprenorphine is also a kappa-opioid receptor antagonist. The partial agonist activity means that opioid receptor antagonists (e.g., an antidote such as naloxone) only partially reverse the effects of buprenorphine. The binding to the mu and kappa receptors results in hyperpolarization and reduced neuronal excitability. Furthermore, buprenorphine slowly dissociates from its receptor. This observation would account for the longer duration of action compared to morphine, the unpredictability of its reversal by opioid antagonists, and its low level of manifest physical dependence. Its receptor fixation half life is 40 minutes which is significantly longer than morphine (milliseconds). </td></tr><tr><th>Absorption</th><td>31% bioavailability (sublingual). Sublingual absorption is also dependent on pH. The length of time the tablet is under the tongue has little effect on absorption. Although buprenorphine is rapidly absorbed from the oral mucosa, the absorption into the systemic is slower. The time to reach peak plasma concentration (Tmax) varies between individuals (range of 40 minutes to 3.5 hours). How buprenorphine is formulated does not affect this pharmacokinetic parameter. It also undergoes extensive first-pass metabolism and as a consequence, has very low oral bioavailability. Coadministration with naloxone does not effect the pharmacokinetics of buprenorphine.</td></tr><tr><th>Volume of distribution</th><td><p>Buprenorphine is very lipophillic and is thus highly distributed. The estimated volume of distribution is 188 &#8211; 335 L when given intravenously. It is able to cross into the placenta and breast milk.</p></td></tr><tr><th>Protein binding</th><td>96% protein bound to alpha- and beta-globulin. </td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic. Buprenorphine undergoes both N-dealkylation to norbuprenorphine and glucuronidation. The N-dealkylation pathway is mediated by cytochrome P-450 3A4 isozyme. Norbuprenorphine, an active metabolite and has one-fifth of the pharmacologic activity of the parent compound, can further undergo glucuronidation.</p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Buprenorphine</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002793" target="_blank">Cytochrome P450 2C9</a></li>
<li><a href="/biodb/bio_entities/BE0002362" target="_blank">Cytochrome P450 3A5</a></li>
<li><a href="/biodb/bio_entities/BE0002887" target="_blank">Cytochrome P450 2C8</a></li>
<li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li></ul></td><td><a href="/metabolites/DBMET00174">Norbuprenorphine</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/175">Details</a></td></tr><tr><td>Buprenorphine</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li>
<li><a href="/biodb/bio_entities/BE0002362" target="_blank">Cytochrome P450 3A5</a></li>
<li><a href="/biodb/bio_entities/BE0003612" target="_blank">Cytochrome P450 3A7</a></li></ul></td><td><a href="/metabolites/DBMET00175">Hydroxybuprenorphine</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/176">Details</a></td></tr><tr><td>Buprenorphine</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0003538" target="_blank">UDP-glucuronosyltransferase 1-9</a></li></ul></td><td><a href="/metabolites/DBMET00176">Buprenorphine glucuronide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/177">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00174">Norbuprenorphine</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01295">Hydroxynorbuprenorphine</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1460">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00175">Hydroxybuprenorphine</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01295">Hydroxynorbuprenorphine</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1461">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>Buprenorphine, like morphine and other phenolic opioid analgesics, is metabolized by the liver and its clearance is related to hepatic blood flow. It is primarily eliminated via feces (as free forms of buprenorphine and norbuprenorphine) while 10 - 30% of the dose is excreted in urine (as conjugated forms of buprenorphine and norbuprenorphine). </td></tr><tr><th>Half life</th><td>IV administration, 0.3 mg = 1.2 - 7.2 hours (mean 2.2 hours);
Sublingual administration = 37 hours. </td></tr><tr><th>Clearance</th><td><p>Clearance may be higher in children than in adults. <br>
Plasma clearance rate, IV administration, anaesthetized patients = 901.2 &#177; 39.7 mL/min;<br>
Plasma clearance rate, IV administration, healthy subjects = 1042 &#8211; 1280 mL/min.</p></td></tr><tr><th>Toxicity</th><td>Manifestations of acute overdose include pinpoint pupils, sedation, hypotension, respiratory depression and death.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9055</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9401</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.6893</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.9126</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.5192</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.6992</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Inhibitor
        </td>
        <td>0.5797</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8366</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Substrate</td>
        <td>0.8919</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.8142</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9153</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8692</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.6721</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7801</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8322</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.9212</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.7448
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9391
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            1.0
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          3.1511 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.8366
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.586
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Purdue pharma lp</li>
<li>Reckitt benckiser pharmaceuticals inc</li>
<li>Bedford laboratories div ben venue laboratories inc</li>
<li>Hospira inc</li>
<li>Pharmaforce inc</li>
<li>Barr laboratories inc</li>
<li>Roxane laboratories inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://orders.a-smeds.com">A-S Medication Solutions LLC</a></li>
<li><a href="http://www.bedfordlabs.com">Bedford Labs</a></li>
<li><a href="http://www.benvenue.com">Ben Venue Laboratories Inc.</a></li>
<li><a href="http://bryantranchprepack.com">Bryant Ranch Prepack</a></li>
<li><a href="http://www.hospira.com">Hospira Inc.</a></li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li><a href="http://www.pharmaforceinc.com">Pharmaforce Inc.</a></li>
<li><a href="http://www.prepaksys.com">Prepak Systems Inc.</a></li>
<li><a href="http://www.purduepharma.com">Purdue Pharma LP</a></li>
<li><a href="http://www.rebelrx.com">Rebel Distributors Corp.</a></li>
<li><a href="http://www.rb.com">Reckitt Benckiser Inc.</a></li>
<li><a href="http://www.remedyrepack.com">Remedy Repack</a></li>
<li><a href="http://www.roxane.com">Roxane Labs</a></li>
<li><a href="http://www.tevapharm.com">Teva Pharmaceutical Industries Ltd.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Injection, solution</td><td>Intravenous</td><td>0.3 mg/mL</td></tr><tr><td>Patch</td><td>Transdermal</td><td>5 mcg/hr; 10 mcg/hr; 20 mcg/hr</td></tr><tr><td>Tablet</td><td>Sublingual</td><td>2 mg, 8 mg</td></tr></tbody></table></td></tr><tr><th>Prices</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="prices"><thead><tr><th>Unit description</th><th>Cost</th><th>Unit</th></tr></thead><tbody><tr><td>Buprenex 0.3 mg/ml Solution (1 Box Contains Five 1ml Box)</td><td>46.39USD</td><td>box</td></tr><tr><td>Subutex 8 mg Sublingual Tabs</td><td>10.2USD</td><td>tab</td></tr><tr><td>Subutex 8 mg tablet sl</td><td>9.4USD</td><td>tablet</td></tr><tr><td>Buprenorphine 8 mg tablet sl</td><td>7.74USD</td><td>tablet</td></tr><tr><td>Buprenex 0.3 mg/ml ampul</td><td>6.96USD</td><td>ml</td></tr><tr><td>Subutex 2 mg Sublingual Tabs</td><td>5.59USD</td><td>tab</td></tr><tr><td>Subutex 2 mg tablet sl</td><td>5.0USD</td><td>tablet</td></tr><tr><td>Buprenorphine 2 mg tablet sl</td><td>4.14USD</td><td>tablet</td></tr><tr><td>Buprenorphine 0.3 mg/ml vial</td><td>2.96USD</td><td>ml</td></tr></tbody></table><div class="alert alert-warning clearfix">DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.</div></td></tr><tr><th>Patents</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="patents"><thead><tr><th>Country</th><th>Patent Number</th><th>Approved</th><th>Expires (estimated)</th></tr></thead><tbody><tr><td>United States</td><td>5968547</td><td>1997-09-29</td><td>2017-09-29</td></tr><tr><td>United States</td><td>5240711</td><td>1993-11-28</td><td>2010-11-28</td></tr><tr><td>Canada</td><td>2276170</td><td>2007-12-04</td><td>2018-02-24</td></tr><tr><td>Canada</td><td>2030178</td><td>1995-08-15</td><td>2010-11-16</td></tr></tbody></table></td></tr><tr id="properties"><th class="divider" colspan="2">Properties</th></tr><tr><th>State</th><td>solid</td></tr><tr><th>Experimental Properties</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr><tr><td>logP</td><td>4.98</td><td>AVDEEF,A ET AL. (1996)</td></tr><tr><td>pKa</td><td>8.31 (at 25 &#176;C)</td><td>AVDEEF,A ET AL. (1996)</td></tr></table></td></tr><tr><th>Predicted Properties</th><td class="data-table-container"><table class="table table-condensed table-striped"><thead><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr></thead><tbody><tr><td>water solubility</td><td>1.68e-02 g/l</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>4.53</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>3.55</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#logp_logd">ChemAxon</a></td></tr><tr><td>logS</td><td>-4.4</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>pKa (strongest acidic)</td><td>7.5</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>pKa (strongest basic)</td><td>12.54</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>physiological charge</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>hydrogen acceptor count</td><td>5</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>hydrogen donor count</td><td>2</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>polar surface area</td><td>62.16</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topolgical_surface">ChemAxon</a></td></tr><tr><td>rotatable bond count</td><td>5</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>refractivity</td><td>131.76</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#refractivity">ChemAxon</a></td></tr><tr><td>polarizability</td><td>53.11</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>number of rings</td><td>7</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>bioavailability</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>rule of five</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Ghose filter</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Veber's rule</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>MDDR-like rule</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="references"><th class="divider" colspan="2">References</th></tr><tr><th>Synthesis Reference</th><td><span class="citations"><p>Kazuhisa Ninomiya, Yasuhiro Fukushima, Mutsuo Okumura, Yuko Hosokawa, &#8220;Buprenorphine percutaneous absorption preparation.&#8221; U.S. Patent US6090405, issued August, 1992.</p></span><a class="wishart-link-out" href="https://www.google.com/?tbm=pts#q=6090405&amp;tbm=pts" target="_blank">US6090405 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><th>General Reference</th><td><span class="citations"><ol>
	<li>Huang P, Kehner GB, Cowan A, Liu-Chen LY: Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. J Pharmacol Exp Ther. 2001 May;297(2):688-95. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11303059">Pubmed</a></li>
	<li>Bodkin JA, Zornberg GL, Lukas SE, Cole JO: Buprenorphine treatment of refractory depression. J Clin Psychopharmacol. 1995 Feb;15(1):49-57. <a href="http://www.ncbi.nlm.nih.gov/pubmed/7714228">Pubmed</a></li>
	<li><span class="caps">FDA</span> label</li>
	<li>Elkader A, Sproule B: Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence. Clin Pharmacokinet. 2005;44(7):661-80. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15966752">Pubmed</a></li>
</ol></span></td></tr><tr><th>External Links</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Resource</th><th>Link</th></tr></thead><tbody><tr><td>KEGG Drug</td><td><a class="wishart-link-out" href="http://www.genome.jp/dbget-bin/www_bget?drug:D07132" target="_blank">D07132 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>KEGG Compound</td><td><a class="wishart-link-out" href="http://www.genome.jp/dbget-bin/www_bget?cpd:C08007" target="_blank">C08007 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PubChem Compound</td><td><a class="wishart-link-out" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=40400" target="_blank">40400 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PubChem Substance</td><td><a class="wishart-link-out" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46505782" target="_blank">46505782 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChEBI</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=3216" target="_blank">3216 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChEMBL</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL1201894" target="_blank">CHEMBL1201894 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Therapeutic Targets Database</td><td><a class="wishart-link-out" href="http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP001353" target="_blank">DAP001353 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PharmGKB</td><td><a class="wishart-link-out" href="http://www.pharmgkb.org/drug/PA448685" target="_blank">PA448685 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>RxList</td><td><a class="wishart-link-out" href="http://www.rxlist.com/cgi/generic3/suboxone.htm" target="_blank">http://www.rxlist.com/cgi/generic3/suboxone.htm <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drugs.com</td><td><a class="wishart-link-out" href="http://www.drugs.com/cdi/buprenorphine.html" target="_blank">http://www.drugs.com/cdi/buprenorphine.html <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Wikipedia</td><td><a class="wishart-link-out" href="http://en.wikipedia.org/wiki/Buprenorphine" target="_blank">Buprenorphine <span class="glyphicon glyphicon-new-window"> </span></a></td></tr></tbody></table></td></tr><tr><th>ATC Codes</th><td>N02AE01<ul class="atc-drug-tree"><li><a href="/atc/N#N">N &#8212; NERVOUS SYSTEM</a></li><li><a href="/atc/N02#N02">N02 &#8212; ANALGESICS</a></li><li><a href="/atc/N02A#N02A">N02A &#8212; OPIOIDS</a></li><li><a href="/atc/N02AE#N02AE">N02AE &#8212; Oripavine derivatives</a></li></ul>N07BC01<ul class="atc-drug-tree"><li><a href="/atc/N#N">N &#8212; NERVOUS SYSTEM</a></li><li><a href="/atc/N07#N07">N07 &#8212; OTHER NERVOUS SYSTEM DRUGS</a></li><li><a href="/atc/N07B#N07B">N07B &#8212; DRUGS USED IN ADDICTIVE DISORDERS</a></li><li><a href="/atc/N07BC#N07BC">N07BC &#8212; Drugs used in opioid dependence</a></li></ul></td></tr><tr><th>AHFS Codes</th><td><ul><li>28:08.12 </li></ul></td></tr><tr><th>PDB Entries</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>FDA label</th><td><a href="/system/fda_labels/DB00921.pdf?1265922810">show</a>(345 KB)</td></tr><tr><th>MSDS</th><td><a href="/system/msds/DB00921.pdf?1373407071">show</a>(196 KB)</td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB06274">Alvimopan</a></td><td>Opioids like buprenorphine may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation. Consider therapy modification.</td></tr><tr><td><a href="/drugs/DB01072">Atazanavir</a></td><td>Atazanavir may increase the serum concentration of Buprenorphine. Buprenorphine may decrease the serum concentration of Atazanavir. Avoid use of buprenorphine in patients receiving atazanavir without ritonavir boosting due to possible decreases in atazanavir exposure. In patients receiving buprenorphine with atazanavir/ritonavir, monitor for increased buprenorphine effects and consider dose reductions if patients experience adverse effects. </td></tr><tr><td><a href="/drugs/DB00872">Conivaptan</a></td><td>Conivaptan may increase the serum concentration of CYP3A4 Substrates like buprenorphine. Upon completion/discontinuation of conivaptan, allow at least 7 days before initiating therapy with drugs that are CYP3A4 substrates. </td></tr><tr><td><a href="/drugs/DB00450">Droperidol</a></td><td>Droperidol may enhance the CNS depressant effect of CNS Depressants like buprenorphine. Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use. </td></tr><tr><td><a href="/drugs/DB06414">Etravirine</a></td><td>Buprenorphine, when used concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to monitor for a decrease in buprenorphine levels (ie. reduced analgesia, and signs of opioid withdrawal).  </td></tr><tr><td><a href="/drugs/DB01247">Isocarboxazid</a></td><td>Buprenorphine may enhance the adverse/toxic effect of MAO Inhibitors like isocarboxazid. When possible, avoid use of buprenorphine in patients who have used a monoamine oxidase inhibitor within the past 14 days due to possible severe adverse effects. </td></tr><tr><td><a href="/drugs/DB00601">Linezolid</a></td><td>Buprenorphine may enhance the adverse/toxic effect of MAO Inhibitors like linezolid. When possible, avoid use of buprenorphine in patients who have used a monoamine oxidase inhibitor within the past 14 days due to possible severe adverse effects. </td></tr><tr><td><a href="/drugs/DB01171">Moclobemide</a></td><td>Buprenorphine may enhance the adverse/toxic effect of MAO Inhibitors like moclobemide. When possible, avoid use of buprenorphine in patients who have used a monoamine oxidase inhibitor within the past 14 days due to possible severe adverse effects. </td></tr><tr><td><a href="/drugs/DB00780">Phenelzine</a></td><td>Buprenorphine may enhance the adverse/toxic effect of MAO Inhibitors like phenelzine. When possible, avoid use of buprenorphine in patients who have used a monoamine oxidase inhibitor within the past 14 days due to possible severe adverse effects. </td></tr><tr><td><a href="/drugs/DB01168">Procarbazine</a></td><td>Buprenorphine may enhance the adverse/toxic effect of MAO Inhibitors like procarbazine. When possible, avoid use of buprenorphine in patients who have used a monoamine oxidase inhibitor within the past 14 days due to possible severe adverse effects. </td></tr><tr><td><a href="/drugs/DB01367">Rasagiline</a></td><td>Buprenorphine may enhance the adverse/toxic effect of MAO Inhibitors like rasagiline. When possible, avoid use of buprenorphine in patients who have used a monoamine oxidase inhibitor within the past 14 days due to possible severe adverse effects. </td></tr><tr><td><a href="/drugs/DB01037">Selegiline</a></td><td>Buprenorphine may enhance the adverse/toxic effect of MAO Inhibitors like selegiline. When possible, avoid use of buprenorphine in patients who have used a monoamine oxidase inhibitor within the past 14 days due to possible severe adverse effects. </td></tr><tr><td><a href="/drugs/DB00976">Telithromycin</a></td><td>Telithromycin may reduce clearance of Buprenorphine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Buprenorphine if Telithromycin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00752">Tranylcypromine</a></td><td>Buprenorphine may enhance the adverse/toxic effect of MAO Inhibitors like tranylcypromine. When possible, avoid use of buprenorphine in patients who have used a monoamine oxidase inhibitor within the past 14 days due to possible severe adverse effects. </td></tr><tr><td><a href="/drugs/DB00427">Triprolidine</a></td><td>The CNS depressants, Triprolidine and Buprenorphine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00582">Voriconazole</a></td><td>Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of buprenorphine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of buprenorphine if voriconazole is initiated, discontinued or dose changed.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>